With IPOs quiet, let’s hear it for the series Cs

With the IPO market still chilly, it’s no surprise that the number and size of late-stage venture rounds rose in the first half of 2024. 

It’s the third straight half for biotech series C rounds and beyond to rise and the most such rounds, at 54, since 2H21, when biotechs raised 69 late-stage rounds...